Mirrx Therapeutics this month scored a major victory in its efforts to secure European patent protection on its microRNA inhibition technology when a Danish court dismissed a lawsuit filed against the company by Santaris Pharma alleging misappropriation of trade secrets.

Having been cleared of wrongdoing, Mirrx and its founder Thorleif Moller have asked the European Patent Office to resume its review of a patent application covering the firm’s core technology, which had been put on hold for more than three years pending a final court ruling.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.